| Assessment Status | Rapid Review Complete |
| HTA ID | 24046 |
| Drug | Tenecteplase |
| Brand | Metalyse® |
| Indication | Tenecteplase (Metalyse®) is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage. |
| Assessment Process | |
| Rapid review commissioned | 08/11/2024 |
| Rapid review completed | 27/11/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tenecteplase be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. April 2025